Antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate

The emergence of antibiotic-resistant bacteria is a rising health crisis that requires the development of new antibacterial agents.  Cationic steroids disrupt bacterial membranes via physical and chemical mechanisms that prevent bacteria from evolving resistance to membrane-permeabilizing cationic amphipathic molecules. 

Researchers in the Diamond Lab have identified a new method of use for the cationic corticosteroid disubstituted dexamethasone spermine (D2S) as an anti-bacterial agent for both Gram-positive (e.g. MRSA) and Gram-negative (e.g. E. coli) organisms that can cause life-threatening situations, particularly in hospital-based infections. D2S has been demonstrated to exhibit antibacterial activity against clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa from cystic fibrosis sputa and biofilms.  Furthermore, D2S enhances S. aureus susceptibility to antibiotics, including amoxicillin, tetracycline, and amikacin.

• Small cationic steroid
• Resists proteolytic activity of pepsin
• D2S maintained in ascites, cerebrospinal fluid, saliva, and bronchoalveolar lavage fluid
• Enhanced S. aureus susceptibility to antibiotics
• Adaptable to large-scale manufacturing

• Antibacterial development
• Anti-inflammatory agent

License